Psychedelic Medicine
March 28, 2026
Levi Neal, Hannah E. Shaw, Brenda M. Gannon et al.
Background: There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but...
Journal of psychopharmacology (Oxford, England)
2026
Jack E Henningfield, Sandra D Comer, Matthew L Banks et al.
5 citations
Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...
Journal of Pharmacology and Experimental Therapeutics
January 25, 2024
Hannah E. Shaw, D. R. Patel, Brenda M. Gannon et al.
Abuse of novel arylcyclohexylamines (ACX) poses risks for toxicities, including adverse neurocognitive effects. In vivo effects of ring-substituted analogs of phencyclidine (PCP), eticyclidine (PCE), and ketamine are understudied. Adult male National Institutes of Health Swiss mice were used to assess locomotor effects of PCP and its 3-OH, 3-MeO, 3-Cl, and 4-MeO analogs, PCE and its 3-OH and...
Psychedelic medicine (New Rochelle, N.Y.)
September 1, 2023
Harpreet Kaur, Sedat Karabulut, James W Gauld et al.
10 citations
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal...
Neuropharmacology
August 19, 2017
Michael D. Berquist, W. Hyatt, Jonathan J. Bauer-Erickson et al.
Methoxetamine (MXE) is a novel drug of abuse that is structurally similar to phencyclidine (PCP). In the present study, rats were trained to discriminate PCP from saline and substitution tests were performed with arylcyclohexylamines PCP, eticyclidine (PCE), tenocyclidine (TCP), and MXE. PCP and PCE engendered PCP-lever selection in all subjects, whereas MXE and TCP produced PCP-lever selection...
The Journal of pharmacology and experimental therapeutics
December 1, 2014
Douglas A Smith, Jessica M Bailey, Diarria Williams et al.
31 citations
The serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor is a potential therapeutic target to a host of neuropsychiatric conditions, but agonist actions at this site are linked to abuse-related hallucinogenic effects that may limit therapeutic efficacy of chronic drug administration. Tolerance to some effects of hallucinogens has been observed in humans and laboratory animals, but the...
Journal of Neuroscience
November 12, 2014
Michael H. Baumann, Ernesto Solis, Lucas R. Watterson et al.
157 citations
The abuse of synthetic psychoactive substances known as "designer drugs," or "new psychoactive substances" (NPS), is increasing at an alarming rate. NPS are purchased as alternatives to traditional illicit drugs of abuse and are manufactured to circumvent laws regulating the sale and use of controlled substances. Synthetic cathinones (i.e., "bath salts") and synthetic cannabinoids (i.e.,...
The Journal of pharmacology and experimental therapeutics
November 1, 2009
K S Murnane, N Murai, Leonard L. Howell et al.
34 citations
3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine more commonly known as the drug of abuse "ecstasy." The acute and persistent neurochemical effects of MDMA in the mice are distinct from those in other species. MDMA shares biological effects with both amphetamine-type stimulants and mescaline-type hallucinogens, which may be attributable to distinct effects of its two...
The Journal of pharmacology and experimental therapeutics
June 2009
William E Fantegrossi, Naoki Murai, Brian O Mathúna et al.
3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse with mixed stimulant- and hallucinogen-like effects. The aims of the present studies were to establish discrimination of S(+)-MDMA, R(-)-MDMA, or their combination as racemic MDMA in separate groups of mice to assess cross-substitution tests among all three compounds, to determine the time courses of the training doses, to assess...
The FASEB Journal
March 1, 2008
Kevin Sean Murnane, Leonard L. Howell, William E Fantegrossi
3,4‐Methylenedioxymethamphetamine (MDMA) is an amphetamine derivative with increasingly widespread abuse. MDMA has been difficult to classify as a stimulant or hallucinogen because it shares effects with both drug classes. Furthermore, racemic MDMA is composed of two isomers that vary in terms of behavioral effects rather than simple potency differences. Specifically, the R(−) isomer of MDMA...
Experimental and Clinical Psychopharmacology
February 1, 2008
William E Fantegrossi
30 citations
The chiral nature of the MDMA molecule gives rise to two enantiomers, each of which is biologically active. This review attempts to cover the author's research into the in vivo effects of MDMA and its enantiomers, as well as other relevant publications which pertain to this topic. No particular differences between the capacities of racemic MDMA and its enantiomers to maintain behavior were...
Pharmacology, biochemistry, and behavior
January 2008
William E Fantegrossi, Chad J Reissig, Elyse B Katz et al.
N,N-dipropyltryptamine (DPT) is a synthetic tryptamine hallucinogen which has been used psychotherapeutically in humans, but has been studied preclinically only rarely. In the present studies, DPT was tested in a drug-elicited head-twitch assay in mice, and in rats trained to discriminate lysergic acid diethylamide (LSD), N,N-dimethyl-4-phosphoryloxytryptamine (psilocybin), or...
Pharmacology, biochemistry, and behavior
2006
William E Fantegrossi, A W Harrington, C L Kiessel et al.
144 citations
Few studies have examined the effects of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) in vivo. In these studies, 5-MeO-DIPT was tested in a drug-elicited head twitch assay in mice where it was compared to the structurally similar hallucinogen N,N-dimethyltryptamine (N,N-DMT) and challenged with the selective serotonin (5-HT)2A antagonist M100907, and in a lysergic acid diethylamide (LSD)...
Behavioural Pharmacology
December 1, 2005
William E Fantegrossi, Kelly M Kugle, Leander J. Valdés et al.
80 citations
Salvinorin A is a pharmacologically active diterpene that occurs naturally in the Mexican mint Ska Maria Pastora (Salvia divinorum) and represents the first naturally occurring kappa-opioid receptor agonist. The chemical structure of salvinorin A is novel among the opioids, and thus defines a new structural class of kappa-opioid-receptor selective drugs. Few studies have examined the effects of...
Psychopharmacology
September 1, 2005
William E Fantegrossi, Andrew W Harrington, Justin R Eckler et al.
72 citations
Few studies have examined the effects of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in vivo. 2C-T-7 was tested in a drug-elicited head twitch assay in mice and in several drug discrimination assays in rats; 2C-T-7 was compared to the phenylisopropylamine hallucinogen R(-)-1-(2,5-dimethoxy-4-methylphenyl)-2aminopropane (DOM) in both assays, with or without pretreatment with the...
Behavioural Pharmacology
March 1, 2004
William E Fantegrossi, James H Woods, Gail Winger
99 citations
Relatively few studies have assessed the reinforcing effects of hallucinogenic compounds, and no such studies have attempted to engender contingent responding for these compounds in animals with behavioral histories that include experience with serotonergically mediated reinforcing effects. The objectives of the present study were to investigate the capacity of several hallucinogenic compounds...